{"brief_title": "Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer", "brief_summary": "The purpose of this study is to estimate the efficacy and safety of OSI-211 and topotecan in patients with relapsed epithelial ovarian cancer.", "condition": ["Ovarian Neoplasms"], "intervention_type": ["Drug"], "intervention_name": ["OSI-211 (Liposomal Lurtotecan)"], "criteria": "Inclusion Criteria: - Confirmed relapsed ovarian cancer. - Measurable disease greater than or equal to 20 mm (or greater than or equal to 10 mm on spiral CT scan). - One or two prior regimens of chemotherapy. At least one regimen must have contained cisplatin or carboplatin. - At least three weeks since prior chemotherapy and recovery from any related toxicities. - At least four weeks since prior radiotherapy and recovery from any related toxicities.", "gender": "Female", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Ovarian Cancer", "mesh_term": ["Ovarian Neoplasms", "Neoplasms, Glandular and Epithelial", "Topotecan", "Lurtotecan"], "id": "NCT00046800"}